JP2008044969A - 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法 - Google Patents

免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法 Download PDF

Info

Publication number
JP2008044969A
JP2008044969A JP2007284431A JP2007284431A JP2008044969A JP 2008044969 A JP2008044969 A JP 2008044969A JP 2007284431 A JP2007284431 A JP 2007284431A JP 2007284431 A JP2007284431 A JP 2007284431A JP 2008044969 A JP2008044969 A JP 2008044969A
Authority
JP
Japan
Prior art keywords
melanoma
cell lines
antigens
methods
cell line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007284431A
Other languages
English (en)
Inventor
Drew M Pardoll
エム． パードル ドゥリュー
Elizabeth M Jaffee
エム． ジャフィー エリザベス
Adam Adler
アドゥラー アダム
Suzanne L Topalian
エル． トパリアン スザンヌ
Steven A Rosenberg
エイ． ローゼンバーグ スティーヴン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
US Government
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
US Government
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, US Government, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2008044969A publication Critical patent/JP2008044969A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

【課題】従来技術では達成できなかった効果を有する、免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法の提供。
【解決手段】(a) １または２以上の免疫優性な共有黒色腫抗原を発現する黒色腫細胞株を取得し、 (b) 未改変黒色腫細胞株に比べてサイトカインの産生レベルが増加し得るように該黒色腫細胞株を改変し、(c) 黒色腫を有するかあるいは黒色腫が発生する危険のある哺乳動物宿主に該黒色腫細胞株を投与することを含む、黒色腫の治療または予防方法。
【選択図】なし

Description
本発明によって以下が提供される：

Claims (1)

  1. 本願明細書に記載されるような、免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法。
JP2007284431A 1996-08-16 2007-10-31 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法 Withdrawn JP2008044969A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2409896P 1996-08-16 1996-08-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP50973298A Division JP2001517206A (ja) 1996-08-16 1997-08-04 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011168822A Division JP2012001548A (ja) 1996-08-16 2011-08-01 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Publications (1)

Publication Number Publication Date
JP2008044969A true JP2008044969A (ja) 2008-02-28

Family

ID=21818860

Family Applications (5)

Application Number Title Priority Date Filing Date
JP50973298A Withdrawn JP2001517206A (ja) 1996-08-16 1997-08-04 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2007284431A Withdrawn JP2008044969A (ja) 1996-08-16 2007-10-31 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2011168822A Withdrawn JP2012001548A (ja) 1996-08-16 2011-08-01 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2013218131A Withdrawn JP2014012738A (ja) 1996-08-16 2013-10-21 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2016043177A Pending JP2016106137A (ja) 1996-08-16 2016-03-07 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP50973298A Withdrawn JP2001517206A (ja) 1996-08-16 1997-08-04 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011168822A Withdrawn JP2012001548A (ja) 1996-08-16 2011-08-01 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2013218131A Withdrawn JP2014012738A (ja) 1996-08-16 2013-10-21 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2016043177A Pending JP2016106137A (ja) 1996-08-16 2016-03-07 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Country Status (8)

Country Link
US (1) US6187306B1 (ja)
EP (1) EP0929318B1 (ja)
JP (5) JP2001517206A (ja)
AT (1) ATE283069T1 (ja)
AU (1) AU3889997A (ja)
CA (1) CA2263503C (ja)
DE (1) DE69731756T2 (ja)
WO (1) WO1998006746A2 (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
WO1999047178A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Novel complementing receptor-ligand pairs and adoptive immunotherapy using same
GB9810040D0 (en) * 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
DE19905501B4 (de) * 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
WO2001098464A2 (en) * 2000-06-22 2001-12-27 Aventis Pasteur Limited Continuous adherent melanocyte cell line
US20040191229A1 (en) 2002-10-09 2004-09-30 Link Charles J. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
GB2424070B (en) * 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
CA2526120A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
RU2636532C2 (ru) 2005-05-27 2017-11-23 Онкиммьюн Лимитед Улучшенные способы иммуноанализа
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
CA2646671A1 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US8574848B2 (en) * 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
US9133309B2 (en) * 2009-10-23 2015-09-15 Dow Corning Toray Co., Ltd. Organopolysiloxane copolymer
CN108472314A (zh) 2015-07-31 2018-08-31 明尼苏达大学董事会 修饰的细胞和治疗方法
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07278193A (ja) * 1994-02-16 1995-10-24 Akzo Nobel Nv 黒色腫関連抗原ポリペプチド、そのエピトープ及び黒色腫のワクチン
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595653A (en) 1981-06-09 1986-06-17 Lee Biomolecular Research Laboratories, Inc. Process for assaying cellular immunity
US5045320A (en) 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ATE129746T1 (de) 1990-09-14 1995-11-15 Univ Johns Hopkins Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems.
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
AU677165B2 (en) * 1991-10-04 1997-04-17 Johns Hopkins University School Of Medicine, The The regulation of systemic immune responses utilizing cytokines and antigens
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07278193A (ja) * 1994-02-16 1995-10-24 Akzo Nobel Nv 黒色腫関連抗原ポリペプチド、そのエピトープ及び黒色腫のワクチン
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens

Also Published As

Publication number Publication date
DE69731756T2 (de) 2005-12-15
AU3889997A (en) 1998-03-06
JP2014012738A (ja) 2014-01-23
EP0929318A2 (en) 1999-07-21
DE69731756D1 (de) 2004-12-30
ATE283069T1 (de) 2004-12-15
JP2012001548A (ja) 2012-01-05
CA2263503C (en) 2012-04-10
EP0929318B1 (en) 2004-11-24
CA2263503A1 (en) 1998-02-19
WO1998006746A3 (en) 1998-05-07
WO1998006746A2 (en) 1998-02-19
JP2016106137A (ja) 2016-06-16
US6187306B1 (en) 2001-02-13
JP2001517206A (ja) 2001-10-02

Similar Documents

Publication Publication Date Title
JP2008044969A (ja) 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2008086326A (ja) ゲノム性要素を使用する遺伝子の操作および発現
EP1376584A3 (en) System and method for automatically generating video cliplets from digital video
JP2005270111A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2006230410A (ja) ヒトｐａｋ６５
EP0867816A3 (en) File management apparatus and method therefor
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
DE59508864D1 (de) MONOKLONALER ANTIKÖRPER GEGEN CD44v6
HUP9700926A2 (hu) D3-vitamin-analógok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP1283465A3 (en) Transforming & caching computer programs
ES2143666T3 (es) P-amidinobencilamidas dipeptidicas con restos sulfonilo, o bien aminosulfonilo n-terminales.
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
AR006612A1 (es) Composicion y procedimiento para la deformacion permanente del cabello
NO993806L (no) FremgangsmÕte for fremstilling av ioderte kontrastmidler og mellomprodukter for disse
JPS5328431A (en) Copier
DK532679A (da) Fremgangsmaade til fremstilling af 2-aryl-3,4-diaza-bicyclo (4,1,0)hepten-(2)-on-(5).
DE69709639D1 (de) Verfahren zur herstellung von phenylheterocyclen die als cox-2 inhibitoren verwendet werden können
BR9914146A (pt) Peptidil prolil cis-trans isomerases
DE69615537T2 (de) Helicobacter pylori antigen
SU627922A1 (ru) Цанговый патрон
TR199701391T1 (xx) Yeni bir �imento �r�n� ve bunu �retmenin y�ntemi.
EP1041457A3 (en) Special image reproducing and observing device
ATE148694T1 (de) Verfahren zur herstellung von 3(5)- methylpyrazolen
IT1240124B (it) Metodo per ritoccare le caratteristiche di funzionamento di dispositivi ottici integrati.

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110531

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110630

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110801

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111102

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120302